MAXIMUS(MMS) - 2025 Q3 - Quarterly Report

Special Note Regarding Forward-Looking Statements This section identifies forward-looking statements by specific terminology and outlines risks that could cause actual results to differ materially from projections - Forward-looking statements are identified by words such as 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'opportunity,' 'could,' 'potential,' 'believe,' 'project,' 'estimate,' 'expect,' 'continue,' 'forecast,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will,' and similar references to future periods[8] - Important factors that could cause actual results to differ materially include a failure to meet performance requirements, ability to compete and price contracts, effects of legislative or government budgetary changes, impact of U.S. government actions, ability to manage growth and integrate acquired businesses, outcomes of reviews or audits, ability to manage debt, cybersecurity incidents, ability to attract and retain personnel, and effects of emerging technologies like AI and ML[9] Part I - Financial Information Item 1. Financial Statements This section presents Maximus's unaudited consolidated financial statements and detailed notes on accounting policies, segments, and other financial items Consolidated Statements of Operations Consolidated Statements of Operations ($) | Metric | For the Three Months Ended June 30, 2025 ($) | For the Three Months Ended June 30, 2024 ($) | For the Nine Months Ended June 30, 2025 ($) | For the Nine Months Ended June 30, 2024 ($) | | :--- | :--- | :--- | :--- | :--- | | Revenue | $1,348.4 million | $1,314.9 million | $4,112.9 million | $3,990.3 million | | Cost of revenue | $988.9 million | $982.6 million | $3,113.0 million | $3,040.4 million | | Gross profit | $359.5 million | $332.3 million | $999.9 million | $949.9 million | | Operating income | $165.7 million | $141.7 million | $405.4 million | $376.7 million | | Net income | $106.0 million | $89.8 million | $243.7 million | $234.4 million | | Basic EPS | $1.87 | $1.47 | $4.22 | $3.83 | | Diluted EPS | $1.86 | $1.46 | $4.20 | $3.81 | | Dividends declared per share | $0.30 | $0.30 | $0.90 | $0.90 | - Revenue increased by 2.5% for the three months ended June 30, 2025, and by 3.1% for the nine months ended June 30, 2025, compared to the respective prior periods[15] - Net income grew by 18.1% for the three months ended June 30, 2025, and by 4.0% for the nine months ended June 30, 2025, year-over-year[15] Consolidated Statements of Comprehensive Income Consolidated Statements of Comprehensive Income ($) | Metric | For the Three Months Ended June 30, 2025 ($) | For the Three Months Ended June 30, 2024 ($) | For the Nine Months Ended June 30, 2025 ($) | For the Nine Months Ended June 30, 2024 ($) | | :--- | :--- | :--- | :--- | :--- | | Net income | $106.0 million | $89.8 million | $243.7 million | $234.4 million | | Foreign currency translation adjustments | $7.3 million | $0.4 million | $21.5 million | $4.1 million | | Net losses on cash flow hedges, net of tax | $(1.6) million | $(1.2) million | $(1.7) million | $(7.4) million | | Other comprehensive income/(loss) | $5.7 million | $(0.8) million | $19.8 million | $(3.3) million | | Comprehensive income | $111.7 million | $89.0 million | $263.6 million | $231.1 million | - Comprehensive income increased by 25.6% for the three months and 14.0% for the nine months ended June 30, 2025, compared to the prior year periods[18] - Foreign currency translation adjustments significantly contributed to other comprehensive income, increasing from $0.4 million to $7.3 million for the three months, and from $4.1 million to $21.5 million for the nine months ended June 30, 2025[18] Consolidated Balance Sheets Consolidated Balance Sheets ($) | Metric | June 30, 2025 ($) | September 30, 2024 ($) | Change ($) | | :--- | :--- | :--- | :--- | | Cash and cash equivalents | $59.8 million | $183.1 million | $(123.3) million | | Accounts receivable, net | $1.42 billion | $879.5 million | $542.8 million | | Total current assets | $1.61 billion | $1.20 billion | $404.5 million | | Total assets | $4.46 billion | $4.13 billion | $330.8 million | | Total current liabilities | $706.2 million | $807.5 million | $(101.4) million | | Long-term debt, non-current portion | $1.61 billion | $1.09 billion | $517.0 million | | Total liabilities | $2.69 billion | $2.29 billion | $400.6 million | | Total shareholders' equity | $1.77 billion | $1.84 billion | $(69.8) million | - Accounts receivable, net, increased significantly by $542.8 million from September 30, 2024, to June 30, 2025, indicating potential delays in cash collections[21] - Long-term debt, non-current portion, increased by $517.0 million, contributing to a rise in total liabilities[21] Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows ($) | Metric | For the Nine Months Ended June 30, 2025 ($) | For the Nine Months Ended June 30, 2024 ($) | Change ($) | | :--- | :--- | :--- | :--- | | Net cash (used in)/provided by operating activities | $(220.0) million | $351.4 million | $(571.4) million | | Net cash used in investing activities | $(57.1) million | $(97.2) million | $40.1 million | | Net cash provided by/(used in) financing activities | $146.8 million | $(229.8) million | $376.6 million | | Net change in cash, cash equivalents, and restricted cash | $(130.4) million | $25.7 million | $(156.1) million | - The company reported net cash used in operating activities of $220.0 million for the nine months ended June 30, 2025, a significant decrease from $351.4 million provided in the prior year, primarily due to delays in cash collections[23] - Net cash provided by financing activities increased to $146.8 million, compared to net cash used of $229.8 million in the prior year, driven by increased borrowings and common stock repurchases[23] Consolidated Statements of Changes in Shareholders' Equity Consolidated Statements of Changes in Shareholders' Equity ($) | Metric | Balance at September 30, 2024 ($) | Balance as of June 30, 2025 ($) | Change ($) | | :--- | :--- | :--- | :--- | | Common Stock Amount | $598.3 million | $627.5 million | $29.2 million | | Accumulated Other Comprehensive Loss | $(32.5) million | $(12.6) million | $19.8 million | | Retained Earnings | $1,277.0 million | $1,158.2 million | $(118.8) million | | Total Equity | $1,842.8 million | $1,773.0 million | $(69.8) million | - Total shareholders' equity decreased by $69.8 million from September 30, 2024, to June 30, 2025, primarily due to significant purchases of Maximus common stock ($306.4 million for the nine months ended June 30, 2025) and cash dividends paid[25][82] - Accumulated other comprehensive loss improved by $19.8 million, driven by foreign currency translation adjustments and cash flow hedge reclassifications[25][78] Notes to Consolidated Financial Statements These notes provide essential details and context for the consolidated financial statements, covering accounting principles, segment performance, and financial disclosures 1. Organization - Maximus, a Virginia corporation established in 1975, is celebrating its 50th anniversary and serves as a leading strategic partner to government agencies, aiming to improve public service delivery[30] 2. Significant Accounting Policies - The consolidated financial statements are prepared in accordance with U.S. GAAP and SEC regulations, with all intercompany balances and transactions eliminated[31] - The preparation of financial statements requires management to make estimates and assumptions, particularly concerning revenue recognition, cost estimation, realizability of long-lived assets, income taxes, and contingencies[34] - The capitalized software balance includes $41.3 million related to technology for new services within the U.S. Services Segment, which is continuously monitored for recoverability[35] 3. Business Segments - Maximus operates through three business segments: U.S. Federal Services, U.S. Services, and Outside the U.S., each delivering distinct solutions to government clients[37] Revenue and Operating Income by Segment (For the Three Months Ended June 30, 2025 vs. 2024) ($) | Segment | Revenue 2025 ($) | Revenue 2024 ($) | Operating Income 2025 ($) | Operating Income 2024 ($) | | :--- | :--- | :--- | :--- | :--- | | U.S. Federal Services | $761.2 million | $683.3 million | $137.9 million | $106.1 million | | U.S. Services | $439.8 million | $472.3 million | $45.0 million | $61.5 million | | Outside the U.S. | $147.4 million | $159.3 million | $5.9 million | $(1.4) million | Revenue and Operating Income by Segment (For the Nine Months Ended June 30, 2025 vs. 2024) ($) | Segment | Revenue 2025 ($) | Revenue 2024 ($) | Operating Income 2025 ($) | Operating Income 2024 ($) | | :--- | :--- | :--- | :--- | :--- | | U.S. Federal Services | $2.32 billion | $2.06 billion | $355.9 million | $258.4 million | | U.S. Services | $1.33 billion | $1.45 billion | $139.6 million | $195.5 million | | Outside the U.S. | $458.7 million | $479.9 million | $18.9 million | $(0.9) million | 4. Revenue Recognition - Revenue is recognized over time as performance obligations are satisfied, typically for a series of distinct services where the customer receives benefits concurrently[46] Revenue by Service Type (For the Nine Months Ended June 30, 2025 vs. 2024) ($) | Service Type | 2025 ($) | % of Total 2025 | 2024 ($) | % of Total 2024 | | :--- | :--- | :--- | :--- | :--- | | Program Operations | $2.05 billion | 49.7% | $1.96 billion | 49.0% | | Clinical Services | $1.54 billion | 37.3% | $1.40 billion | 35.1% | | Employment & Other | $274.5 million | 6.7% | $346.4 million | 8.7% | | Technology Solutions | $256.8 million | 6.2% | $285.8 million | 7.2% | | Total revenue | $4.11 billion | 100% | $3.99 billion | 100% | Revenue by Customer Type (For the Nine Months Ended June 30, 2025 vs. 2024) ($) | Customer Type | 2025 ($) | % of Total 2025 | 2024 ($) | % of Total 2024 | | :--- | :--- | :--- | :--- | :--- | | U.S. federal government agencies | $2.27 billion | 55.1% | $2.02 billion | 50.5% | | Total U.S. state government agencies | $1.34 billion | 32.5% | $1.44 billion | 36.1% | | International government agencies | $451.6 million | 11.0% | $469.0 million | 11.8% | | Other | $58.6 million | 1.4% | $65.2 million | 1.6% | | Total revenue | $4.11 billion | 100% | $3.99 billion | 100% | - As of June 30, 2025, remaining performance obligations totaled approximately $330 million, with 63% expected to be settled within the next 12 months[59] 5. Earnings Per Share Weighted Average Number of Shares - Earnings Per Share (in thousands) | Metric | For the Three Months Ended June 30, 2025 | For the Three Months Ended June 30, 2024 | For the Nine Months Ended June 30, 2025 | For the Nine Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Basic weighted average shares outstanding | 56,683 | 61,079 | 57,776 | 61,233 | | Dilutive effect of unvested RSUs and PSUs | 301 | 302 | 324 | 262 | | Denominator for diluted earnings per share | 56,984 | 61,381 | 58,100 | 61,495 | - The diluted earnings per share calculation for the nine months ended June 30, 2025, excluded approximately 142,000 unvested anti-dilutive restricted stock units[60] 6. Divestitures - In December 2024, Maximus sold its businesses in Australia and Korea, resulting in divestiture-related charges of $39.3 million, which included $21.3 million of previously unrealized foreign exchange losses[62] - An indemnification to the buyer for the Australia and Korea divestiture is estimated at a fair value of $11.0 million[62] - In November 2023, the company sold its businesses in Italy and Singapore, and its employment services business in Canada, recording a loss of $1.0 million[63] 7. Debt and Derivatives Details of Debt ($) | Debt Type | June 30, 2025 ($) | September 30, 2024 ($) | | :--- | :--- | :--- | | Term Loan A (TLA) | $864.4 million | $641.9 million | | Term Loan B (TLB) | $495.0 million | $498.8 million | | Revolver | $310.0 million | — | | Subsidiary loan agreements | $1.2 million | $5.2 million | | Total debt principal | $1.67 billion | $1.15 billion | | Long-term debt | $1.61 billion | $1.09 billion | - On March 20, 2025, the company amended its credit agreement, increasing the Term Loan A facility by $250 million for general corporate purposes[64] - Maximus utilizes interest rate swaps as cash flow hedges to reduce interest rate risk, with a total notional amount of $900 million as of June 30, 2025[67] - As of June 30, 2025, the effective interest rate, including original issuance costs and discount rate, was 5.5%[68] 8. Fair Value Measurements Fair Value Measurements as of June 30, 2025 ($) | Item | Level 1 ($) | Level 2 ($) | Level 3 ($) | Balance ($) | | :--- | :--- | :--- | :--- | :--- | | Deferred compensation assets - Rabbi Trust | $38.1 million | — | — | $38.1 million | | Interest rate swap - $375 million notional value (asset) | — | $8.0 million | — | $8.0 million | | Interest rate swap - $525 million notional value (liability) | — | $1.1 million | — | $1.1 million | | Indemnification liabilities | — | — | $11.0 million | $11.0 million | - Accumulated other comprehensive loss improved from $(32.5) million at September 30, 2024, to $(12.6) million at June 30, 2025, primarily due to foreign currency translation adjustments and reclassifications from derivatives[78] 9. Equity - Maximus grants Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) under its 2021 Omnibus Incentive Plan, with vesting periods ranging from one to four years for RSUs and three years for PSUs based on performance[79] - During the nine months ended June 30, 2025, approximately 364 thousand RSUs and 154 thousand PSUs were issued[80] - The Board of Directors authorized an increase to the stock purchase program, allowing for up to $400 million in common stock repurchases, with $65.8 million remaining available as of June 30, 2025[81][82] - The company purchased approximately 4.1 million common shares at a cost of $309.5 million during the nine months ended June 30, 2025[82] 10. Other Items Cash, Cash Equivalents, and Restricted Cash ($) | Metric | June 30, 2025 ($) | September 30, 2024 ($) | | :--- | :--- | :--- | | Cash and cash equivalents | $59.8 million | $183.1 million | | Restricted cash | $45.6 million | $52.6 million | | Total | $105.4 million | $235.8 million | Accounts Receivable, Net ($) | Metric | June 30, 2025 ($) | September 30, 2024 ($) | | :--- | :--- | :--- | | Billed and billable receivables | $1.03 billion | $734.8 million | | Unbilled receivables | $401.5 million | $149.5 million | | Allowance for credit losses | $(9.5) million | $(4.8) million | | Accounts receivable, net | $1.42 billion | $879.5 million | - The company has a Receivables Purchase Agreement (RPA) with Wells Fargo Bank N.A., allowing the sale of up to $200.0 million in U.S.-originated accounts receivable[85] - For the nine months ended June 30, 2025, $574.2 million in gross fair value of receivables were transferred under the RPA, generating $570.7 million in cash[87] 11. Commitments and Contingencies - Maximus is subject to audits, investigations, and reviews related to government contracts, which could lead to penalties, fines, suspension, or debarment[88] - Multiple class action lawsuits and individual actions have been filed against the company following the May 2023 MOVEit cybersecurity incident, alleging negligence and compromise of personal information[90][91][95] - These federal cases have been centralized in a Multidistrict Litigation (MDL) in the District of Massachusetts, and the company has accrued an amount within a range of possible outcomes for these matters[92][96] 12. Subsequent Event - On July 5, 2025, the Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on August 31, 2025, with an anticipated cash payment of approximately $16.9 million[97] Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section provides management's perspective on Maximus's business, financial condition, and operational results, including strategic plans and liquidity Business Overview - Maximus's mission is 'Moving People Forward' by partnering with government agencies to deliver public services, including health insurance eligibility, clinical services, and technology services[99] - The company's strategic plan, introduced in fiscal year 2022, focuses on three pillars: Customer Services, Digitally Enabled (e.g., Maximus Total Experience Management - TXM), Future of Health, and Advanced Technologies for Modernization[100][101] - The strategy also emphasizes optimizing processes, simplifying structure under the 'Maximus Forward' initiative, and prioritizing employee attraction, retention, and development[100] Financial Overview - Maximus experienced short-term delays in cash flow during the second quarter of the current fiscal year due to administrative delays in billing and contract approval with customers in the U.S. Federal and U.S. Services Segments[102] - These delays resulted in a significant increase in receivables balances and necessitated additional borrowings under the revolving credit facility, leading to higher interest expense[102] - Significant progress in resolving these delays was made in July 2025, with a return to normal receivables anticipated by the end of the fourth quarter of fiscal year 2025[102] Results of Operations This section provides a consolidated overview of financial performance, detailing revenue, profit, and segment-specific results for the period Consolidated Results of Operations (For the Nine Months Ended June 30, 2025 vs. 2024) ($) | Metric | 2025 ($) | 2024 ($) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | $4.11 billion | $3.99 billion | +3.1% | | Gross profit | $999.9 million | $949.9 million | +5.3% | | Operating income | $405.4 million | $376.7 million | +7.6% | | Net income | $243.7 million | $234.4 million | +4.0% | | Diluted EPS | $4.20 | $3.81 | +10.2% | - Selling, general, and administrative expenses for the nine months ended June 30, 2025, include $39.3 million in divestiture-related charges from the sale of businesses in the Outside the U.S. Segment[111] - The effective income tax rate for the nine months ended June 30, 2025, increased to 29.2% from 25.3% in the prior year, primarily due to the disposition of businesses in Australia and Korea[115] U.S. Federal Services Segment U.S. Federal Services Segment - Financial Results ($) | Metric | For the Nine Months Ended June 30, 2025 ($) | For the Nine Months Ended June 30, 2024 ($) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | $2.32 billion | $2.06 billion | +12.5% | | Operating income | $355.9 million | $258.4 million | +37.7% | | Gross profit percentage | 25.9% | 24.5% | +1.4 pp | | Operating margin percentage | 15.3% | 12.5% | +2.8 pp | - Revenue growth was driven by clinical programs, including medical assessments, increased volumes from the Honoring our PACT Act, and support provided to the Federal Emergency Management Agency (FEMA)[119] - The segment anticipates a full-year operating margin of approximately 15% in fiscal year 2025[120] U.S. Services Segment U.S. Services Segment - Financial Results ($) | Metric | For the Nine Months Ended June 30, 2025 ($) | For the Nine Months Ended June 30, 2024 ($) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | $1.33 billion | $1.45 billion | -7.9% | | Operating income | $139.6 million | $195.5 million | -28.6% | | Gross profit percentage | 23.4% | 25.5% | -2.1 pp | | Operating margin percentage | 10.5% | 13.5% | -3.0 pp | - The decrease in revenue and operating income is attributed to the return to normal activity levels after higher volumes from Medicaid redetermination activities in the first three quarters of fiscal year 2024[123] - The segment anticipates a full-year operating margin of approximately 10.5% for fiscal year 2025[123] Outside the U.S. Segment Outside the U.S. Segment - Financial Results ($) | Metric | For the Nine Months Ended June 30, 2025 ($) | For the Nine Months Ended June 30, 2024 ($) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | $458.7 million | $479.9 million | -4.4% | | Operating income/(loss) | $18.9 million | $(0.9) million | N/A (moved to profit) | | Gross profit percentage | 18.7% | 15.5% | +3.2 pp | | Operating margin percentage | 4.1% | -0.2% | +4.3 pp | - This segment transitioned from a near breakeven to profitability between fiscal years 2024 and 2025, despite a revenue decrease[127] - The divestiture of operations in Australia and Korea in the first quarter of fiscal year 2025 reduced revenue and costs but provided a benefit to margin[128] - Organic growth was achieved across the portfolio, including the Functional Assessment Services (FAS) contract in the United Kingdom[128] - The segment anticipates a full-year operating margin ranging between 3% and 5% for fiscal year 2025[129] Liquidity and Capital Resources - Primary liquidity sources include cash on hand ($59.8 million as of June 30, 2025), cash from operations, and availability under revolving credit facilities[130] - Net cash used in operations was $220.0 million for the first nine months of fiscal year 2025, a significant decrease from $351.4 million provided in the prior year, primarily due to delays in cash collections from large customers[135] - Days Sales Outstanding (DSO) increased to 96 days at June 30, 2025, compared with 61 days at September 30, 2024, reflecting the collection delays[138] - The company utilized $306.4 million to repurchase approximately 4.1 million common shares during the nine months ended June 30, 2025[140] - Maximus was in compliance with all financial covenants of its Credit Agreement as of June 30, 2025, with a Consolidated Net Total Leverage Ratio of 2.09 and a Consolidated Net Interest Coverage Ratio of 9.22[144][148] Free Cash Flow (Non-GAAP) ($) | Metric | For the Nine Months Ended June 30, 2025 ($) | For the Nine Months Ended June 30, 2024 ($) | | :--- | :--- | :--- | | Net cash (used in)/provided by operating activities | $(220.0) million | $351.4 million | | Purchases of property and equipment and capitalized software | $(55.7) million | $(82.2) million | | Free cash flow (Non-GAAP) | $(275.7) million | $269.2 million | Critical Accounting Policies and Estimates - There have been no material changes to the critical accounting policies and estimates previously disclosed in the 2024 Form 10-K during the nine months ended June 30, 2025[151] Non-GAAP and Other Measures - Maximus utilizes non-GAAP measures such as organic growth, Adjusted EBITDA, and free cash flow to provide users with a clearer understanding of business performance by excluding the effects of currency fluctuations, acquisitions, divestitures, and amortization of intangible assets[152][154][158] Non-GAAP Adjusted Results (For the Nine Months Ended June 30, 2025 vs. 2024) ($) | Metric | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | Operating income | $405.4 million | $376.7 million | | Adjusted EBITDA (Non-GAAP) | $541.3 million | $470.4 million | | Net income | $243.7 million | $234.4 million | | Adjusted net income excluding amortization of intangible assets and divestiture-related charges (Non-GAAP) | $334.0 million | $285.9 million | | Diluted earnings per share | $4.20 | $3.81 | | Adjusted diluted earnings per share excluding amortization of intangible assets and divestiture-related charges (Non-GAAP) | $5.75 | $4.65 | - Adjusted EBITDA (Non-GAAP) for the nine months ended June 30, 2025, increased to $541.3 million from $470.4 million in the prior year, and Adjusted diluted EPS (Non-GAAP) rose to $5.75 from $4.65[158] Item 3. Quantitative and Qualitative Disclosures About Market Risk This section confirms no material changes to market risk disclosures, covering interest rates, foreign currency, and counterparty risk - No material changes to the company's market rate risk disclosures (interest rates, foreign currency exchange rates, and counterparty risk) occurred during the nine months ended June 30, 2025[159] - The company uses derivative instruments to manage selected interest rate exposures[159] Item 4. Controls and Procedures Management evaluated disclosure controls and procedures as effective, with no material changes in internal control over financial reporting - The company's disclosure controls and procedures were evaluated and deemed effective as of June 30, 2025, ensuring timely and accurate reporting[160] - No changes in internal control over financial reporting that materially affected or are reasonably likely to materially affect internal control over financial reporting were identified during the last fiscal quarter[161] Part II - Other Information Item 1. Legal Proceedings This section cross-references detailed disclosures on legal proceedings, commitments, and contingencies in Note 11 of the financial statements - Information on legal proceedings is cross-referenced to 'Note 11. Commitments and Contingencies' in Part I, Item 1 of this Quarterly Report[163] Item 1A. Risk Factors This section confirms no material changes to risk factors previously disclosed in the 2024 Form 10-K and 2025 Q2 Form 10-Q - No material changes to the risk factors discussed in the 2024 Form 10-K, as supplemented by the 2025 Q2 Form 10-Q, occurred during the three months ended June 30, 2025[164] Item 2. Unregistered Sales of Equity Securities and Use of Proceeds This item is not applicable to the company for the reporting period - This item is not applicable[165] Item 3. Defaults Upon Senior Securities This item is not applicable to the company for the reporting period - This item is not applicable[165] Item 4. Mine Safety Disclosures This item is not applicable to the company for the reporting period - This item is not applicable[165] Item 5. Other Information No director or officer adopted, modified, or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement - No director or officer adopted, modified, or terminated a 'Rule 10b5-1 trading arrangement' or 'non-Rule 10b5-1 trading arrangement' during the three months ended June 30, 2025[167] Item 6. Exhibits This section lists all exhibits filed with the Quarterly Report on Form 10-Q, including certifications and taxonomy documents - Exhibits include certifications of the Chief Executive Officer and Chief Financial Officer (pursuant to Sections 302 and 906 of Sarbanes-Oxley Act), Amended and Restated By-laws, and Inline XBRL Instance, Schema, Calculation, Definition, Label, and Presentation Linkbase Documents[168] Signatures This section contains the required signatures of the principal executive and financial officers, certifying the report submission - The report was signed by Bruce L. Caswell, President and Chief Executive Officer, and David W. Mutryn, Chief Financial Officer, on August 7, 2025[173]